Kornimate/medical-research-clean huggingface dataset:
prevalence study of sleep apnea in women with preeclampsia

Conditions: Preeclampsia

Summary: hypothesis: the prevalence of sleep apnea is greater in pregnant women with preeclampsia than in pregnant women without preeclampsia.the presence of sleep apnea will be associated with poor blood pressure control, worsening blood pressure during sleep and evidence of fetal distress. the usual treatment for sleep apnea is to have the patient breathe pressurized air through a mask. this is called continuous positive airway pressure (cpap). in preeclamptic women with sleep apnea, use of cpap will result in improved blood pressure control and reduced fetal distress.

sleep apnea is common in the adult population. in middle aged men, the presence of sleep apnea has been correlated with hypertension, cardiovascular disease and mood disorders. sleep apnea is not as well studied in women and even less is known about sleep apnea in pregnant women. however, preliminary evidence suggests that the incidence is quite high, particularly in women with severe preeclampsia. we propose to perform sleep studies on 30 women with preeclampsia and 30 healthy pregnant controls. in addition to the usual sleep study monitoring, we will also measure beat-to-beat blood pressure through non-invasive monitoring and we will do continuous electronic fetal monitoring. women found to have sleep apnea will have a repeat study in which cpap therapy is applied, and be provided cpap therapy for nightly use at home.

Eligibility criteria:
inclusion criteria: * pregnant women \>18 years of age exclusion criteria: * significant medical conditions that would be expected to affect maternal- fetal outcomes * need for admission to hospital, so that it transfer to the sleep would compromise maternal-fetal safety

Keywords: preeclampsia sleep apnea cpap
protocolized reduction of non-resuscitation fluids vs usual care in septic shock feasibility trial

Conditions: Shock, Septic

Summary: the objectives of this feasibility trial are to assess the efficacy and feasibility of methods and procedures of a protocol purposed to compare a reduction of administration of non-resuscitation fluids to usual care in patients with septic shock.


Eligibility criteria:
inclusion criteria: * adult (≥ 18 years of age) * septic shock according to the sepsis 3 criteria: suspected or confirmed infection and infusion of vasopressor/inotrope to maintain mean arterial pressure of 65 mmhg or above despite adequate fluid resuscitation and lactate of 2 mmol/l or above at any time following icu admission when there was a simultaneous need for vasopressor/inotrope. * inclusion within 12 hours after icu admission. exclusion criteria: * confirmed or suspected pregnancy
[18f]-arag for the detection of t-cell activation in advanced non-small cell lung cancer patients undergoing pd-1/pd-l1-directed therapy

Conditions: Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8

Summary: this trial studies how well \[18f\]-arag works in detecting t-cell activation in patients with non-small cell lung cancer that has spread to other places in the body (advanced), who are undergoing pd-1/pd-l1-directed therapy. \[18f\]-arag is a "radiotracer" which attaches to immune cells directed at the cancer and shines a light that can be seen using a special camera, called a "positron emission tomography" or "pet" scanner. \[18f\]-arag may improve the ability to detect a response of the cancer in the body to immunotherapy.

primary objectives: i. to quantify fluorine f 18 ara-g (\[18f\]-arag) uptake (standardized uptake value \[suv\]) in advanced non-small cell lung cancer (nsclc) tumor (primary, nodal, and metastatic sites) at baseline and after 1 dose of anti-pd-1/pd-l1 therapy in both patients treated with pd-1/pd-l1 monotherapy and in patients treated with immunotherapy/chemotherapy combination therapy. ii. to correlate change in \[18f\]-arag uptake before and after the start of therapy with radiographic response in patients treated with immunotherapy. outline: patients receive \[18f\]-arag intravenously (iv) and then undergo pet/ct over 2 hours at baseline and within 2 weeks after starting immunotherapy. patients may also undergo blood sample collection. after completion of study treatment, patients are followed for up to 12 months.

Eligibility criteria:
inclusion criteria: * this study is open to all adult subjects with histological confirmation of nsclc planned to undergo treatment with a pd-1 or pd-l1 inhibitor either as monotherapy or as combination therapy with concurrent chemotherapy as treatment for advanced/metastatic disease * eastern cooperative oncology group (ecog) performance status of 0, 1, 2 or 3 at the time of enrollment * patient with life expectancy \>= 24 weeks from the time of screening to the study * ability to sign and understand the institutional review board (irb)-approved consent form in english * ability to remain motionless for up to 30 minutes per scan exclusion criteria: * patients with severe claustrophobia (patients with milder forms of claustrophobia that can be successfully allayed with oral anxiolytic therapy are allowed) * severe impaired renal function with estimated glomerular filtration rate \< 30 ml/min/1.73 m\^2 and/or on dialysis * pregnancy * breast feeding an infant * prior treatment with anti-pd-1/pd-l1 inhibitor * localized/locally advanced disease with anti pd-1/pd-l1 given as consolidation
a natural history study of molybdenum cofactor and isolated sulfite oxidase deficiencies

Conditions: Molybdenum Cofactor Deficiency; Isolated Sulfite Oxidase Deficiency

Summary: primary objective: characterize the natural history of mocd type a in terms of survival secondary objectives: 1. evaluate blood and urine for biochemical markers 2. evaluate head circumference, seizure activity and neurologic outcomes 3. to evaluate brain mri 4. compare blood and urine analysis, head circumference, seizure activity and neurologic outcomes to mri findings


Eligibility criteria:
inclusion criteria: 1. both living and deceased patients of any age will be considered for study inclusion. 2. diagnosis of mocd or isolated sox deficiency 3. documented informed consent exclusion criteria: 1. mocd type a patient who was in study alx-mcd-501 2. deceased patients with unknown genotype (as of amendment 4)

Keywords: natural history study
sevoflurane induced emergence agitation

Conditions: Emergence Agitation

Summary: investigators evaluated the effect of intranasal ketamine or alfentanil addition to oral midazolam for prevention of emergence agitation.seventy-eight, 1-8 year-old children, undergoing urological surgery with sevoflurane anesthesia was included in the study. all the children received oral midazolam 0.5 mg/kg 40 minutes before anesthesia induction then enrolled to one of the study groups, randomly. ketamine group (group mk; n=26) patients were given 2mg/kg intranasal ketamine whereas, alfentanil group (group ma; n=25) were given 10microgram/kg intranasal alfentanil 8-10 min before the induction of anesthesia. saline group (group ms; n=27) received intranasal isotonic saline.parental separation, mask acceptance were evaluated with a 4- point scale. emergence agitation was evaluated with pediatric anesthesia emergence delirium score.


Eligibility criteria:
inclusion criteria: * 1- 8 years * american society of anesthesiologist (asa) i-ii, * patients undergoing procedures below the umbilicus exclusion criteria: * cardiac diseases * pulmonary diseases * hepatic diseases * renal diseases * psychological or emotional disorders

Keywords: child sevoflurane emergence delirium general anesthesia premedication.
prosthetic valve sweing ring injection by antiboitics can affect the rate of postoperative infective endocarditis?

Conditions: Prosthetic Valve Endocarditis

Summary: follow-up of patients undergoing cardiac valve replacements with prosthetic valve after injection of sewing ring of prosthetic valve with aminoglycoside for prevention of infective endocarditis.


Eligibility criteria:
inclusion criteria: * patients who need cardiac valve replacement for rheumatic or degenerative causes exclusion criteria: * patients undergoing open heart surgery for any cause other than valve replacement * patients who are younger than 20 years old. * patients undergoing valve repair.
interest of pulmonary ultrasound to predict evolution towards bronchopulmonary dysplasia in premature infants at gestational age less than or equal to 34 weeks of gestation

Conditions: Bronchopulmonary Dysplasia

Summary: each year, between 50,000 and 60,000 children are born prematurely in france. among them, 10% are born at 26 - 30 week's gestation and 5% are born before 26 week's gestation. bronchopulmonary dysplasia (bpd) affects at least one-quarter of infants born with a birth weight less than 1500 grams. bpd is defined by the need for oxygen after 28 days of life in any children born prematurely. in addition, the severity of bpd can be categorized as mild (room air tolerated at 36 weeks), moderate (oxygen requirement between 22 and 29 %) and severe (oxygen requirement 30% or need for ventilation support). bronchopulmonary dysplasia is responsible for significant respiratory morbidity and impaired neurological outcomes. pulmonary imaging such as tomodensitometry, mri or scintigraphy can be abnormal and therefore coud theorically be helpful for an early diagnosis. unfortunatelly, theses examinations are irradiating, expensive or difficult to perform in an everyday practice. therefore lung imaging for bpd diagnosis. is not recommanded in current official guidelines. pulmonary ultrasound has already been studied in premature newborns. a pilot study carried out on 21 patients showed that pulmonary ultrasonography at one and two weeks of life could predict the risk of bronchopulmonary dysplasia. the score used in this study was the lus score previously validated by brat et al. advantages of this examination are to be non-invasive and easily performed at the patient's bedside. nevertheless this study focused on a small population with a low number of moderate / severe dysplasia. in addition, czernik et al. have highlighted that the index of myocardial performance of the right ventricle was increased at seven and ten days of life in children who subsequently developed bpd. the investigators propose in this study to evaluate a new prediction score for dbp, the modified lus score, associating the lus score with an echographic evaluation of the right heart (myocardial performance index).


Eligibility criteria:
inclusion criteria: * premature neonates with gestational age less than or equal to 34 weeks of amenorrhea. * hospitalized in the nicu or neanatology unit at limoges university hospital at day 9 +/- 2 and day 15 +/- 2 of life * participation agreement of at least one of the parents. exclusion criteria: * cardiac malformations * congenital lung malformation.

Keywords: bronchopulmonary dysplasia premature newborn ultrasonography
tailored therapy for clarithromycin-resistant h. pylori

Conditions: Helicobacter Pylori Infection

Summary: clarithromycin-resistant h. pylori is the main cause of h. pylori eradication failure. tailored therapy on the basis of detection of a clarithromycin resistance mutation by pcr has been studied recently, however, there have been few studies comparing treatment regimen in patient with clarithromycin-resistant h. pylori. we used sequencing-based clarithromycin resistance mutation and aimed to compare pam (proton pump inhibitor, amoxicilline, metronidazole) regimen and pbmt (proton pump inhibitor, bismuth, metronidazole, tetracyclin) regimen in patient with clarithromycin-resistant h. pylori.


Eligibility criteria:
inclusion criteria: * peptic ulcer disease * h. pylori gastritis * low grade malt lymphoma exclusion criteria: * history of gastric cancer surgery * severe comorbidity (esrd, lc) * hypersensitivity to drug * pregnancy
laparoscopic tubal preservation surgery

Conditions: Ectopic Pregnancy

Summary: traditionally, salpingectomy has been the standard procedure for managing ectopic pregnancy. we would like to evaluate the safety and efficacy of laparoscopic tubal preservation surgery in treating ectopic pregnancies (salpingostomy or salpingotomy) while preserving the fertility outcome of the patients, as well as to identify the factors predicting the presence of persistent ectopic pregnancy after the surgery.

all surgically-treated ectopic pregnancies in women aged 20 and above between 01 january 2009 and 31 december 2016 were identified. cases receiving laparoscopic salpingostomy or laparoscopic salpingotomy were extracted from the database, patient characteristics and surgical outcomes (changes of serumβ-hcg, presence of persistent ectopic pregnancy and subsequent management, subsequent pregnancy) were reviewed from their medical records. univariate and multivariate logistic regression analysis were employed to predict the presence of persistent ectopic pregnancy after laparoscopic tubal preservation surgery.

Eligibility criteria:
inclusion criteria: * women who had laparoscopic tubal preservation surgery (including salpingostomy and salpingotomy) for ectopic pregnancy between january 2009 and november 2016 exclusion criteria: * women with ectopic pregnancy at sites other than fallopian tube (i.e. interstitial, ovary, abdomen)
different endoscopic gastric cancer risk assessments

Conditions: Gastric Cancer Screening

Summary: the kimura-takamoto classification established in japan can observe the extent of gastric atrophy in real-time under endoscopy, and diffuse atrophy also indicates an increased risk of gastric cancer. recent studies have found that the evaluation of intestinal metaplasia score (eggim score) of various stomach parts by electronic staining can well identify olgim iii\\ iv patients. although the kimura-takamoto classification and eggim score can evaluate the risk of gastric cancer in patients, only in cross-sectional studies, it is not clear the diagnostic value of risk assessment in population screening. early gastric cancer has the characteristics of hidden lesions and a high rate of clinical missed diagnosis. concentrating high-risk groups through risk scores is expected to guide endoscopic doctors to conduct a targeted careful examination. however, it is not clear whether kimura-takamoto classification and eggim score can improve the detection rate of early gastric cancer in clinical practice.


Eligibility criteria:
inclusion criteria: * patients aged 40-80 years undergoing gastroscopy * patients intend to undergo esd treatment exclusion criteria: * patients with severe cardiac, cerebral, pulmonary or renal dysfunction or psychiatric disorders who cannot participate in gastroscopy * patients with previous surgical procedures on the stomach * patients with contraindications to biopsy * patients who refuse to sign the informed consent form.
study of a hand-held device plus mobile app versus standard eye care devices in measuring refractive error of the eye

Conditions: Refractive Errors; Astigmatism

Summary: single-center, open-label, prospective study in healthy volunteers desiring refraction for correction of visual acuity to compare a handheld device supported by a mobile application with the phoropter and autorefractor.

single-center, open-label, prospective study in healthy volunteers desiring refraction for correction of visual acuity to compare a handheld device supported by a mobile application with the phoropter and autorefractor in male or female subjects 30 to 65 years of age.

Eligibility criteria:
inclusion criteria: * male or female * age 30 through 65 years at the time of consent * binocular vision * subject desires refraction for correction of visual acuity and vision can be corrected in each eye to 20/20 (logmar 0.0) * willing and able to give informed consent and follow all study procedures and requirements * ability to speak and understand the english language exclusion criteria: * spherical correction \> +8 or \< -10 * using anticholinergic medications (including first-generation antihistamines) or other medications known to affect visual acuity within the greater of 3 days or 5 half-lives prior to enrolling in this study * using an investigational drug or approved therapy for investigational use within the greater of 3 days or 5 half-lives prior to enrolling in this study * has initiated any new medication in the past 2 weeks that, in the best medical judgment of the investigator, would impact their participation in the study or ability to use the device * eye disease, including but not limited to: * glaucoma (≥ 22 mmhg intraocular pressure) * cataracts (≥ 1+ nuclear sclerotic cataract, ≥ 1+ cortical, posterior subcapsular cataract \[any grade using the lens opacities classification system iii\]) * macular degeneration (retinal pigmented epithelium mottling and/or any drusen within 500 μm of macula) * eye infection (corneal ulcer, corneal infiltrates, superficial punctate keratitis) * keratoconus * diabetic neuropathy/retinopathy (≥ mild nonproliferative diabetic retinopathy) * cytomegalovirus retinitis * color blindness (any color deficiency) * diabetic macular edema (evidence of fluid) * amblyopia * chronic or acute uveitis (cells and/or flare in anterior chamber) * strabismus (exotropia, esotropia, and hypertropia) * abnormal astigmatism (mild to severe, \> 5 diopters) * macular hole * eye surgery within the last 12 months (including lasik or lens replacement) * subject does not have the physical dexterity to properly operate the device or the on the smartphone in the investigator's opinion.

Keywords: myopia hyperopia
clinical trial of temisartan/amlodipine & rosuvastatin in subjects with hypertension and hyperlipidemia

Conditions: Hypertension; Hyperlipidemia

Summary: randomized, double-blind, active-controlled, multicenter phase 3 trial to evaluate efficacy and safety of co-administrated temisartan/amlodipine and rosuvastatin in subjects with hypertension and hyperlipidemia.

this trial is a phase 3 study to evaluate efficacy and safety of co-administrated temisartan/amlodipine and rosuvastatin in subjects with hypertension and hyperlipidemia. in "temisartan/amlodipine/rosuvastatin" treatment group, 60 subjects will be assigned and the subjects administer "temisartan/amlodipine/rosuvastatin" 8 for weeks. in "temisartan/amlodipine" treatment group, 60 subjects will be assigned and the subjects administer "temisartan/amlodipine" for 8 weeks. in "temisartan/rosuvastatin" treatment group, 60 subjects will be assigned and the subjects administer "temisartan/rosuvastatin" for 8 weeks.

Eligibility criteria:
inclusion criteria: 1. signed informed consent 2. subjects with hypertension and hyperlipidemia exclusion criteria: 1. patients with known or suspected secondary hypertension 2. other exclusions applied
registry of acute coronary syndrome from university hospital of vigo

Conditions: Acute Coronary Syndrome

Summary: cardochuvi registry was aim to study ischemic and bleeding complication after an acute coronary syndrome (acs), both in-hospital and follow-up events.

cardiochuvi is a retrospective study aim to analyze all consecutively patients admitted by acute coronary syndrome to university hospital alvaro cunqueiro of vigo, between january 2010 to january 2018 the objective of the project was to study cardiac and bleeding complications, such as reinfarction, heart failure, atrial fibrillation, stroke, and bleeding events, together with all-cause and cardiac mortality

Eligibility criteria:
inclusion criteria: * any patient admitted to university hospital alvaro cunqueiro of vigo for acute coronary syndrome. exclusion criteria: * secondary acute coronary syndromes during a hospital admission for another cause (i.e. acute myocardial infarction in the context of a sepsis)

Keywords: acute coronary syndrome; bleeding; dual antiplatelet therapy
arthroscopic rotator cuff repair of full thickness tears with and without arthroscopic acromioplasty

Conditions: Rotator Cuff Tear; Shoulder Impingement Syndrome

Summary: surgical repair of full thickness tears of the rotator cuff is a controversial issue, with several procedures currently being used to treat the tear. the two most common treatments at this point in time are arthroscopic cuff repair with and without acromioplasty. however, an arthroscopic cuff repair without acromioplasty may offer the same degree of improvement as one that includes acromioplasty, but without threatening the shoulder stability that is provided by the acromion and coracoacromial ligament. this prospective study examines the hypothesis that appropriate shoulder function can be restored through the execution of the traditional arthroscopic cuff repair without acromioplasty.

there exists some controversy in the current trend in repair of full thickness tears of the rotator cuff. the two most common treatments at this point in time are arthroscopic cuff repair with and without acromioplasty. the purpose of acromioplasty is to create adequate space for the rotator cuff tendons. arthroscopic acromioplasty involves the removal of the subacromial bursa, resection of the coracoacromial ligament and anteroinferior portion of the acromion, and resection of any osteophytes from the acromioclavicular joint that are thought to be contributing to impingement. however, acromioplasty without cuff repair has been reported to have both good and poor results, showing that the technique may be suspect in repair of full thickness tears alone. the purpose of this study is to compare the effectiveness of arthroscopic cuff repair with acromioplasty to arthroscopic cuff repair without acromioplasty in repair of full thickness tears of the rotator cuff. we hypothesize that there will be a significant clinical improvement in quality of life in patients who receive a rotator cuff repair without acromioplasty compared to those who receive a cuff repair with acromioplasty.

Eligibility criteria:
inclusion criteria: * ages 18 or older * complete rotator cuff tear up to 4 cm in size * persistent pain and functional disability for at least 6 months * failure of conservative treatment * establishment of final eligibility based upon visual exam of rotator cuff tear during surgery and determination of repairability exclusion criteria: * evidence of significant osteoarthritis or cartilage damage in the shoulder * evidence of glenohumeral instability including bankart lesions and labral tears of any type * previous surgeries of the shoulder * evidence of major joint trauma, infection, or necrosis in the shoulder * patients with partial thickness tears of the rotator cuff * patients unable to provide informed consent due to language barrier or mental status * patients with a major medical condition that would affect quality of life and influence the results of the study * patients with worker compensation claims * patients unwilling to be followed for the duration of the study

Keywords: rotator cuff tear tendon repair acromioplasty arthroscopy orthopedic surgery